<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629611</url>
  </required_header>
  <id_info>
    <org_study_id>KGOG4009_Vi-TLH</org_study_id>
    <nct_id>NCT05629611</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Vi-sealer</brief_title>
  <official_title>Efficacy and Safety Evaluation of Advanced Vessel Sealing Device (Vi-sealer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyun Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's primary goal is to compare the efficacy and safety of the novel advanced&#xD;
      hemostatic device(AHD), Vi-Sealer, with conventional AHDs in laparoscopic total hysterectomy&#xD;
      for patients with benign gynecologic neoplasm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vi-Sealer is a reusable advanced bipolar electrode with an interchangeable blade. This study&#xD;
      evaluates the efficacy and safety of the Vi-Sealer by comparing it with other advanced&#xD;
      hemostatic devices, such as Ligasure, Enseal, Thunderbeat, Harmonic scalpel, etc. The&#xD;
      economic evaluation of the device compared with other disposable devices would also be&#xD;
      conducted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2022</start_date>
  <completion_date type="Anticipated">October 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative procedure time</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Measure the time consumed from the initial skin incision to the closure of abdominal trocar sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated blood loss</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated medical cost of device</measure>
    <time_frame>within 6 weeks after intervention</time_frame>
    <description>Medical costs according to hemostatic instrument use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device evaluation score</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Ergonomics and subjective hemostatic performances assessed by surgeons using the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>within 6 weeks after intervention</time_frame>
    <description>Collect only for adverse events that have a relationship with medical devices for clinical trials</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Benign Gynecologic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Study 1 Vi-Sealer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of women undergoing hysterectomy is randomized to the energy device, Vi-sealer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 1 Ligasure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of women undergoing hysterectomy is randomized to the energy device, Ligasure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 2 Vi-sealer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of women undergoing hysterectomy is randomized to the energy device, Vi-sealer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 2 Other AHD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of women undergoing hysterectomy is randomized to energy devices other than Ligasure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vi-Sealer</intervention_name>
    <description>using Reusable device, Vi-Sealer</description>
    <arm_group_label>Study 1 Vi-Sealer</arm_group_label>
    <arm_group_label>Study 2 Vi-sealer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ligasure</intervention_name>
    <description>using Ligasure</description>
    <arm_group_label>Study 1 Ligasure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Other AHD</intervention_name>
    <description>Using other AHDs such as Thunderbeat, Harmonic scalpel, Caiman®, Enseal, etc. except Ligasure</description>
    <arm_group_label>Study 2 Other AHD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 20 to 65 years&#xD;
&#xD;
          2. Clinically diagnosed with benign gynecologic neoplasms (eg. adenomyosis, uterine&#xD;
             fibroids, etc.)&#xD;
&#xD;
          3. Eligible for hysterectomy&#xD;
&#xD;
          4. Signing an written consent form indicating that they understand the purpose of and&#xD;
             procedures required for the study and are willing to participate in the study prior to&#xD;
             any other study-related assessments or procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Large uterus size over 16 weeks of gestational age&#xD;
&#xD;
          2. Cervical or intraligamentary fibroids&#xD;
&#xD;
          3. Severe endometriosis (stage 3 or 4)&#xD;
&#xD;
          4. Suspected malignancy of the uterus or adnexa&#xD;
&#xD;
          5. Contraindicated for the use of energy devices (such as implantable cardioverter&#xD;
             defibrillators, pacemakers)&#xD;
&#xD;
          6. Previous pelvic surgery ≥ 3 times&#xD;
&#xD;
          7. Not suitable for laparoscopic surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyun Park</last_name>
    <phone>+82-031-780-5640</phone>
    <email>p06162006@cha.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Jung Kim</last_name>
      <phone>+82-031-780-5640</phone>
      <email>tooncrunch@naver.com</email>
    </contact>
    <investigator>
      <last_name>Hyun Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Wong C, Goh A, Merkur H. Comparison of surgical outcomes using Gyrus PKS vs LigaSure in total laparoscopic hysterectomy: A randomised controlled trial. Aust N Z J Obstet Gynaecol. 2020 Oct;60(5):790-796. doi: 10.1111/ajo.13217. Epub 2020 Jul 29.</citation>
    <PMID>32729141</PMID>
  </reference>
  <reference>
    <citation>Holloran-Schwartz MB, Gavard JA, Martin JC, Blaskiewicz RJ, Yeung PP Jr. Single-Use Energy Sources and Operating Room Time for Laparoscopic Hysterectomy: A Randomized Controlled Trial. J Minim Invasive Gynecol. 2016 Jan;23(1):72-7. doi: 10.1016/j.jmig.2015.08.881. Epub 2015 Aug 28.</citation>
    <PMID>26318400</PMID>
  </reference>
  <reference>
    <citation>Janssen PF, Brolmann HA, van Kesteren PJ, Bongers MY, Thurkow AL, Heymans MW, Huirne JA. Perioperative outcomes using LigaSure compared with conventional bipolar instruments in laparoscopic hysterectomy: a randomised controlled trial. BJOG. 2011 Dec;118(13):1568-75. doi: 10.1111/j.1471-0528.2011.03089.x. Epub 2011 Sep 6.</citation>
    <PMID>21895949</PMID>
  </reference>
  <reference>
    <citation>Hasanov M, Denschlag D, Seemann E, Gitsch G, Woll J, Klar M. Bipolar vessel-sealing devices in laparoscopic hysterectomies: a multicenter randomized controlled clinical trial. Arch Gynecol Obstet. 2018 Feb;297(2):409-414. doi: 10.1007/s00404-017-4599-y. Epub 2017 Dec 8.</citation>
    <PMID>29222641</PMID>
  </reference>
  <reference>
    <citation>Winter ML, Mendelsohn SA. Total laparoscopic hysterectomy using the harmonic scalpel. JSLS. 1999 Jul-Sep;3(3):185-6.</citation>
    <PMID>10527328</PMID>
  </reference>
  <reference>
    <citation>Shiber LJ, Ginn DN, Jan A, Gaskins JT, Biscette SM, Pasic R. Comparison of Industry-Leading Energy Devices for Use in Gynecologic Laparoscopy: Articulating ENSEAL versus LigaSure Energy Devices. J Minim Invasive Gynecol. 2018 Mar-Apr;25(3):467-473.e1. doi: 10.1016/j.jmig.2017.10.006. Epub 2017 Oct 12.</citation>
    <PMID>29032252</PMID>
  </reference>
  <reference>
    <citation>Rothmund R, Kraemer B, Brucker S, Taran FA, Wallwiener M, Zubke A, Wallwiener D, Zubke W. Laparoscopic supracervical hysterectomy using EnSeal vs standard bipolar coagulation technique: randomized controlled trial. J Minim Invasive Gynecol. 2013 Sep-Oct;20(5):661-6. doi: 10.1016/j.jmig.2013.04.014. Epub 2013 Jun 20.</citation>
    <PMID>23791399</PMID>
  </reference>
  <reference>
    <citation>Lee CL, Wu KY, Huang CY, Yen CF. Comparison of LigaSure tissue fusion system and a conventional bipolar device in hysterectomy via natural orifice transluminal endoscopic surgery (NOTES): A randomized controlled trial. Taiwan J Obstet Gynecol. 2019 Jan;58(1):128-132. doi: 10.1016/j.tjog.2018.11.024.</citation>
    <PMID>30638466</PMID>
  </reference>
  <reference>
    <citation>Honeck P, Wendt-Nordahl G, Bolenz C, Peters T, Weiss C, Alken P, Michel MS, Hacker A. Hemostatic properties of four devices for partial nephrectomy: a comparative ex vivo study. J Endourol. 2008 May;22(5):1071-6. doi: 10.1089/end.2007.0236.</citation>
    <PMID>18429683</PMID>
  </reference>
  <reference>
    <citation>Landman J, Kerbl K, Rehman J, Andreoni C, Humphrey PA, Collyer W, Olweny E, Sundaram C, Clayman RV. Evaluation of a vessel sealing system, bipolar electrosurgery, harmonic scalpel, titanium clips, endoscopic gastrointestinal anastomosis vascular staples and sutures for arterial and venous ligation in a porcine model. J Urol. 2003 Feb;169(2):697-700. doi: 10.1097/01.ju.0000045160.87700.32.</citation>
    <PMID>12544345</PMID>
  </reference>
  <reference>
    <citation>Timm RW, Asher RM, Tellio KR, Welling AL, Clymer JW, Amaral JF. Sealing vessels up to 7 mm in diameter solely with ultrasonic technology. Med Devices (Auckl). 2014 Jul 30;7:263-71. doi: 10.2147/MDER.S66848. eCollection 2014.</citation>
    <PMID>25114600</PMID>
  </reference>
  <reference>
    <citation>Nieboer TE, Steller CJ, Hinoul P, Maxson AJ, Schwiers ML, Miller CE, Coppus SF, Kent AS. Clinical utility of a novel ultrasonic vessel sealing device in transecting and sealing large vessels during laparoscopic hysterectomy using advanced hemostasis mode. Eur J Obstet Gynecol Reprod Biol. 2016 Jun;201:135-9. doi: 10.1016/j.ejogrb.2016.03.035. Epub 2016 Apr 14.</citation>
    <PMID>27124666</PMID>
  </reference>
  <reference>
    <citation>Sandberg EM, la Chapelle CF, van den Tweel MM, Schoones JW, Jansen FW. Laparoendoscopic single-site surgery versus conventional laparoscopy for hysterectomy: a systematic review and meta-analysis. Arch Gynecol Obstet. 2017 May;295(5):1089-1103. doi: 10.1007/s00404-017-4323-y. Epub 2017 Mar 29.</citation>
    <PMID>28357561</PMID>
  </reference>
  <reference>
    <citation>Park JY, Nho J, Cho IJ, Park Y, Kim DY, Suh DS, Kim JH, Nam JH. Laparoendoscopic single-site versus conventional laparoscopic-assisted vaginal hysterectomy for benign or pre-invasive uterine disease. Surg Endosc. 2015 Apr;29(4):890-7. doi: 10.1007/s00464-014-3747-8. Epub 2014 Aug 9.</citation>
    <PMID>25106721</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 31, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CHA University</investigator_affiliation>
    <investigator_full_name>Hyun Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Advanced hemostatic devices</keyword>
  <keyword>Advanced energy devices</keyword>
  <keyword>Ligasure</keyword>
  <keyword>Laparoscopic total hysterectomy</keyword>
  <keyword>Vi-sealer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

